Annexon
ANNX
4.01
-0.02
-0.50%
Annexon
US · ANNX
#3455 by market cap
Listed 2020
4.01
-0.02
-0.50%
Live - 5344 symbols - heartbeat 280s ago
· 2026-10-08 09:08
Pre-market
4.03
+0.50%
After-hours
4.05
+1.00%
Overnight
4.05
+1.00%
- Market cap
- 760.21M
- P/E (TTM)i
- -3.55
- P/Bi
- 4.09
- EPSi
- -1.34
- Div yieldi
- 0.00%
- 52W posi
- 32%
Reader sentiment
Are you bullish or bearish on ANNX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 7.3 percentage points.
Institutional ownership
- Held by institutions
- 101.85% -7.34pp
- Institutions
- 252
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund49.32%
Hedge Fund32.46%
VC/PE Fund13.44%
Public Company4.34%
Insurance Company1.17%
Individual/Insider0.92%
Private Company0.48%
Government Pension Fund0.37%
Endowment Fund0.25%
Top holders as of 2026-06-30
FMR
10.30% · 19.52M sh
Redmile Group, LLC
7.67% · 14.55M sh
BlackRock
7.14% · 13.54M sh
State Street Global Advisors
5.18% · 9.82M sh
Alerce Investment Management L.P.
5.03% · 9.53M sh
BVF Partners L.P.
4.59% · 8.70M sh
Vanguard Capital Management, LLC
4.21% · 7.98M sh
Woodline Partners LP
3.65% · 6.93M sh
MAK Capital One, LLC
3.09% · 5.86M sh
Artal Group S.A.
2.35% · 4.46M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 34 buys · 16 sells
| Name | Role | Stake |
|---|---|---|
| Muneer Satter | Independent Director | 0.43% |
| Douglas Love | Chief Executive Officer | 0.21% |
| Ted Yednock | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | 0.10% |
| William Carson | Independent Director | 0.04% |
| Michael Overdorf | Executive VP & Chief Business Officer | 0.04% |
| Dean Artis | Chief Scientific Officer & Executive VP | 0.04% |
| Jennifer Lew | Chief Financial Officer | 0.03% |
| Jung Choi | Independent Director | 0.02% |
| Jamie Dananberg | Chief Medical Officer | 0.01% |
| Thomas Wiggans | Independent Chairperson | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-23 | Douglas Love | Chief Executive Officer | Open Market Acquisition | +26,065 | $3.83 |
| 2026-08-12 | Thomas Wiggans | Independent Chairperson | Intent to Sell (Form 144) | -2,000 | $5.30 |
| 2026-08-09 | Mark Blumenkranz | Director | Other Derivative Acquisition | +175,000 | $5.39 |
| 2026-07-14 | Thomas Wiggans | Independent Chairperson | Intent to Sell (Form 144) | -2,000 | $6.32 |
| 2026-07-13 | Thomas Wiggans | Independent Chairperson | Intent to Sell (Form 144) | -1,000 | $5.61 |
| 2026-06-10 | Muneer Satter | Independent Director | Other Derivative Acquisition | +65,000 | $4.70 |
| 2026-06-10 | Jung Choi | Independent Director | Other Derivative Acquisition | +65,000 | $4.70 |
| 2026-06-10 | William Waddill | Independent Director | Other Derivative Acquisition | +65,000 | $4.70 |
| 2026-06-10 | Ted Yednock | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | Derivative Exercise and Retained | +30,646 | $1.85 |
| 2026-06-10 | William Jones | Director | Other Derivative Acquisition | +65,000 | $4.70 |
| 2026-06-10 | William Carson | Independent Director | Other Derivative Acquisition | +65,000 | $4.70 |
| 2026-06-10 | Bettina Cockroft | Independent Director | Other Derivative Acquisition | +65,000 | $4.70 |
| 2026-05-27 | Alerce Investment Management L.P. | -- | Open Market Acquisition | +613,497 | $5.41 |
| 2026-05-10 | William Carson | Independent Director | Automatic Acquisition | +8,000 | $5.78 |
| 2026-04-09 | William Carson | Independent Director | Automatic Acquisition | +8,000 | $6.20 |
| 2026-03-09 | William Carson | Independent Director | Automatic Acquisition | +8,000 | $5.67 |
| 2026-03-01 | Dean Artis | Chief Scientific Officer & Executive VP | Open Market Disposition | -5,894 | $5.43 |
| 2026-03-01 | Ted Yednock | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | Open Market Disposition | -5,566 | $5.42 |
| 2026-03-01 | Jennifer Lew | Chief Financial Officer | Open Market Disposition | -5,565 | $5.42 |
| 2026-03-01 | Jamie Dananberg | Chief Medical Officer | Open Market Disposition | -5,820 | $5.43 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:08:31 · For reference only, not investment advice and not tailored to your situation.